Thyroid transcription factor-1, or TTF-1, is one of the most familiar immunohistochemical markers in lung adenocarcinoma diagnostics. It is routinely used to support the diagnosis of pulmonary adenocarcinoma, yet its clinical meaning may extend far beyond pathology labeling. A new Journal of Thoracic Oncology study suggests that TTF-1-negative lung adenocarcinoma identifies a biologically distinct subset with worse outcomes to immune checkpoint inhibitors, chemoimmunotherapy, durvalumab after chemoradiation, and even KRAS G12C inhibitors. In the study cohort of 3,297 patients, TTF-1 negativity was seen in 15% of cases, which is consistent with the long-standing estimate that roughly 15% to 20% of lung adenocarcinomas are TTF-1 negative.
That is what makes this paper important. TTF-1 is already available in routine practice, already reported by pathologists, and already familiar to every thoracic oncology team. The question is whether it should now be taken more seriously as a marker of unfavorable tumor biology and not simply as a diagnostic feature.
Read About Non-Small Cell Lung Cancer on OncoDaily
Why TTF-1 Still Matters in 2026
In metastatic NSCLC, treatment selection is increasingly driven by molecular profiling, PD-L1 expression, and specific resistance mechanisms. But even in this biomarker-rich landscape, there is still room for simple markers that capture broader biological behavior. TTF-1 has been associated for years with a more differentiated pulmonary adenocarcinoma phenotype, while TTF-1 loss has often been linked to smoking-related disease, mucinous biology, and more aggressive behavior. Smaller prior studies had already suggested that TTF-1-positive tumors respond better to immunotherapy-based approaches than TTF-1-negative tumors. What had been missing was a much larger and more integrated analysis across pathology, genomics, immunophenotype, and multiple treatment settings.
The new JTO paper attempts exactly that by pooling data from five institutions as well as large data resources including The Cancer Genome Atlas, the Stand Up To Cancer–Mark Foundation dataset, and POPLAR/OAK. That design allowed the investigators to examine not only outcomes, but also how TTF-1 negativity correlates with smoking history, PD-L1 expression, and co-mutation patterns.
The Genomic and Clinical Profile of TTF-1-Negative Disease
The first major message of the study is that TTF-1-negative lung adenocarcinoma is not just TTF-1-positive disease without staining. It looks different clinically and genomically.
Compared with TTF-1-positive cases, TTF-1-negative tumors were associated with more frequent tobacco exposure and lower PD-L1 expression. Genomically, they were enriched for alterations that thoracic oncologists already recognize as poor-prognosis or treatment-resistant partners, including STK11, KEAP1, SMARCA4, NKX2-1, CDKN2A, and KRAS. These are not random associations. Several of these co-alterations have repeatedly been linked with immune-cold phenotypes, aggressive biology, or worse outcomes to systemic therapy. The fact that they cluster in TTF-1-negative tumors helps explain why the clinical results of this paper are so consistently unfavorable.
That is a clinically relevant point. TTF-1 negativity may not be acting as a single causal biomarker. It may be functioning as a readily visible surrogate for a broader adverse molecular program.
Immunotherapy Outcomes Were Substantially Worse
The most striking part of the paper is the outcome analysis in metastatic disease. Among patients treated with immune checkpoint inhibitor monotherapy, TTF-1-negative tumors performed clearly worse than TTF-1-positive tumors. The objective response rate was 17% versus 28%, median progression-free survival was 2.5 versus 4.4 months, and median overall survival was 9.6 versus 20.2 months. Those are not subtle differences.
These data reinforce earlier signals from smaller studies. In 2022, Nakahama and colleagues reported that patients with TTF-1-positive lung adenocarcinoma treated with PD-1 or PD-L1 inhibitor monotherapy had better outcomes than TTF-1-negative cases, including longer progression-free and overall survival. That earlier dataset was far smaller, but the direction of effect is highly consistent with the new JTO analysis.
So the updated message is not that TTF-1 newly emerged from nowhere. It is that a much larger data set now supports the idea that TTF-1 negativity marks a group less likely to benefit from single-agent immunotherapy.
Chemoimmunotherapy Did Better Than Immunotherapy Alone, but TTF-1-Negative Tumors Still Lagged Behind
It might have been tempting to assume that adding chemotherapy could erase at least some of the disadvantage seen with TTF-1-negative disease. The study suggests otherwise.
Among patients treated with chemoimmunotherapy, TTF-1-negative tumors still had worse outcomes than TTF-1-positive tumors. The objective response rate was 26% versus 41%, median PFS was 4.6 versus 8.2 months, and median OS was 11.2 versus 23.4 months. So while chemoimmunotherapy remains more active than immunotherapy alone in many patients, TTF-1 negativity still identified a distinctly poorer-risk subgroup.
That also aligns with smaller prior work. Katayama and colleagues previously found that TTF-1 positivity was associated with better clinical outcomes in advanced lung adenocarcinoma treated with combined chemoimmunotherapy, again supporting the idea that TTF-1 expression may carry predictive or at least strongly prognostic value in immunotherapy-based regimens.
The Signal Extended Into Stage III Disease
One of the more interesting aspects of the paper is that the TTF-1 effect was not restricted to metastatic immunotherapy cohorts. In patients receiving durvalumab after chemoradiation for unresectable stage III disease, TTF-1-negative tumors also performed worse. Median PFS was 8.0 months versus 24.8 months, and median overall survival was 20.0 months versus not reached for TTF-1-positive disease.
That matters because it suggests this is not only a metastatic-line treatment artifact. TTF-1 negativity may identify a broader treatment-resistant phenotype that remains relevant even in consolidation immunotherapy after definitive chemoradiation.
Even KRAS G12C Inhibitors Were Less Effective
The paper becomes even more provocative when it turns to KRAS G12C-mutant lung adenocarcinoma. TTF-1-negative tumors had worse outcomes to KRAS G12C inhibitors than TTF-1-positive tumors. In that subgroup, ORR was 13% versus 36%, median PFS was 2.7 versus 5.9 months, and median OS was 4.4 versus 12.1 months.
This result fits with an earlier 2025 Nature Medicine analysis of sotorasib efficacy biomarkers, which identified low TTF-1 expression as a major adverse determinant of KRAS G12C inhibitor activity. In that work, tumors with low TTF-1 had markedly shorter PFS and OS after sotorasib than tumors with high TTF-1 expression. The newer JTO study extends that concern beyond a single drug-development context and places it into a broader clinical framework.
This may be one of the most practice-relevant observations in the paper. TTF-1 is inexpensive, widely available, and already checked at diagnosis. If it consistently tracks with poor KRAS G12C inhibitor outcomes, it could become a very practical risk-stratification tool for patients who otherwise appear to have a targetable alteration.
Also Read About KRAS G12C NSCLC: Cracking Resistance on OncoDaily
What This Means for Clinical Practice
The study does not say that TTF-1 should replace PD-L1, NGS, or formal molecular risk stratification. It also does not prove that TTF-1 is independently predictive in every treatment context. But it does strongly suggest that TTF-1-negative lung adenocarcinoma should not be viewed as an ordinary adenocarcinoma subgroup.
In practical terms, a TTF-1-negative result may now deserve more attention in multidisciplinary discussion. It may prompt closer consideration of co-alterations such as STK11, KEAP1, or SMARCA4, greater caution in assuming robust benefit from single-agent immunotherapy, and more awareness that even targeted therapy in the KRAS G12C setting may underperform relative to expectations.
The paper also reinforces a broader lesson in thoracic oncology: routine pathology markers can still carry major biological and therapeutic information, even in the era of high-dimensional molecular testing.
The Bottom Line
Article provide one of the most comprehensive analyses to date of TTF-1-negative lung adenocarcinoma. Their findings support the view that TTF-1 negativity marks a subset enriched for smoking exposure, lower PD-L1 expression, unfavorable co-mutations, and consistently worse outcomes across multiple modern treatment settings. In this dataset, TTF-1-negative tumors performed worse not only with immune checkpoint inhibitors, but also with chemoimmunotherapy, durvalumab after chemoradiation, and KRAS G12C inhibitors.
For clinicians, that makes TTF-1 more than a diagnostic stain. It may be one of the simplest routinely available biomarkers pointing toward a harder-to-treat form of lung adenocarcinoma.
You can read full abstract here